Dihydro-pyrrolopyridinone inhibitors

Abstract

The present invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , and R 5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

1 . A compound of formula (I) or a pharmaceutically acceptable salt thereof, 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is H, C 1 -C 3  alkyl, or C 1 -C 3  haloalkyl; 
         R 2  is H, C 1 -C 3  alkyl, or C 1 -C 3  haloalkyl; 
         R 3  is H, C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, —OR 3a , —NR 3b R 3c , —N(R 3b )C(O)R 3d , —N(R 3b )C(O)NR 3b R 3c , —N(R 3b )S(O) 2 NR 3b R 3c , —C(O)R 3a , —C(O)OR 3a , —C(O)NR 3b R 3c , —S(O)R 3d , —S(O) 2 R 3a , —S(O) 2 NR 3b R 3c , or G 1 ; wherein the C 1 -C 6  alkyl, C 2 -C 6  alkenyl, and C 2 -C 6  alkynyl are each independently unsubstituted or substituted with 1 or 2 substituents independently selected from the group consisting of halogen, G 1 , —OR 3a , and —NR 3b R 3c ; 
         R 3a , R 3b , and R 3c , at each occurrence, are each independently H, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, G 1 , —(C 1 -C 6  alkylenyl)-G 1 , —(C 1 -C 6  alkylenyl)-CN, —(C 1 -C 6  alkylenyl)-OR z1 , or —(C 1 -C 6  alkylenyl)-NR z3 R z4 ; 
         R 3d , at each occurrence, is independently C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, G 1 , or —(C 1 -C 6  alkylenyl)-G 1 ; 
         G 1 , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; and each G 1  is optionally substituted with 1, 2, 3, 4, or 5 R 1g  groups; 
         R 4  is H, C 1 -C 6  alkyl, halogen, or C 1 -C 6  haloalkyl; 
         R 5  is a monocyclic or bicyclic ring selected from the group consisting of aryl and heteroaryl; each of which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , G 2 , —OR a , —OC(O)R b , —OC(O)NR c R d , —SR a , —S(O) 2 R a , —S(O) 2 NR c R d , —C(O)R a , —C(O)OR a , —C(O)NR c R d , —NR c R d , —N(R e )C(O)R b , —N(R e )S(O) 2 R b , —N(R e )C(O)O(R b ), —N(R e )C(O)NR c R d , —N(R e )S(O) 2 NR c R d , —(C 1 -C 6  alkylenyl)-G 2 , —(C 1 -C 6  alkylenyl)-OR a , —(C 1 -C 6  alkylenyl)-OC(O)R b , —(C 1 -C 6  alkylenyl)-OC(O)NR c R d , —(C 1 -C 6  alkylenyl)-S(O) 2 R a , —(C 1 -C 6  alkylenyl)-S(O) 2 NR c R d , —(C 1 -C 6  alkylenyl)-C(O)R a , —(C 1 -C 6  alkylenyl)-C(O)OR a , —(C 1 -C 6  alkylenyl)-C(O)NR c R d , —(C 1 -C 6  alkylenyl)-NR c R d , —(C 1 -C 6  alkylenyl)-N(R e )C(O)R b , —(C 1 -C 6  alkylenyl)-N(R e )S(O) 2 R b , —(C 1 -C 6  alkylenyl)-N(R e )C(O)O(R b ), —(C 1 -C 6  alkylenyl)-N(R e )C(O)NR c R d , —(C 1 -C 6  alkylenyl)-N(R e )S(O) 2 NR c R d , and —(C 1 -C 6  alkylenyl)-CN; 
         R a , R, R d , and R e , at each occurrence, are each independently H, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, C 1 -C 6  haloalkyl, G 2 , or C 1 -C 6  alkyl wherein the C 1 -C 6  alkyl is optionally substituted with one substituent selected from the group consisting of —OR y1 , —NR y3 R y4 , —C(O)OR y1 , —C(O)NR y3 R y4 , —S(O) 2 R y1 , —S(O) 2 NR y3 R y4 , and G 2 ; 
         R b , at each occurrence, is independently C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, C 1 -C 6  haloalkyl, G 2 , or C 1 -C 6  alkyl wherein the C 1 -C 6  alkyl is optionally substituted with one substituent selected from the group consisting of —OR y1 , —NR y3 R y4 , —C(O)OR y1 , —C(O)NR y3 R y4 , —S(O) 2 R y1 , —S(O) 2 NR y3 R y4 , and G 2 ; 
         G 2 , at each occurrence, are each independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; and each G 2  group is optionally substituted with 1, 2, 3, 4, or 5 R 2g  groups; 
         R 1g , at each occurrence, is independently C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , —OR z1 , —OC(O)R z2 , —OC(O)NR z3 R z4 , —SR z1 , —S(O) 2 R z1 , —S(O) 2 NR z3 R z4 , —C(O)R z1 , —C(O)(C 3 -C 6  cycloalkyl), —C(O)OR z1 , —C(O)NR z3 R z4 , —NR z3 R z4 , —N(R z3 )C(O)R z2 , —N(R z3 )S(O) 2 R z2 , —N(R z3 )C(O)O(R z2 ), —N(R z3 )C(O)NR z3 R z4 , —N(R z3 )S(O) 2 NR z3 R z4 , —(C 1 -C 6  alkylenyl)-OR z1 , —(C 1 -C 6  alkylenyl)-OC(O)R z2 , —(C 1 -C 6  alkylenyl)-OC(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-S(O) 2 R z1 , —(C 1 -C 6  alkylenyl)-S(O) 2 NR z3 R z4 , —(C 1 -C 6  alkylenyl)-C(O)R z1 , —(C 1 -C 6  alkylenyl)-C(O)OR z1 , —(C 1 -C 6  alkylenyl)-C(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-NR z3 R z4 , —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)R z2 , —(C 1 -C 6  alkylenyl)-N(R z3 )S(O) 2 R z2 , —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)O(R z2 ), —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-N(R z3 )S(O) 2 NR z3 R z4 , —(C 1 -C 6  alkylenyl)-CN, or —O(phenyl); wherein the phenyl moiety and the C 3 -C 6  cycloalkyl moiety are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of C 1 -C 6  alkyl, halogen, C 1 -C 6  haloalkyl, —OH, —O(alkyl), —O(haloalkyl), CN, and NO 2 ; 
         R 2g , at each occurrence, is independently C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, oxo, —CN, NO 2 , —OR y1 , —OC(O)R y2 , —OC(O)NR y3 R y4 , —SR y1 , —S(O) 2 R y1 , —S(O) 2 NR y3 R y4 , —C(O)R y1 , —C(O)OR y1 , —C(O)NR y3 R y4 , —NR y3 R y4 , —N(R y3 )C(O)R y2 , —N(R y3 )S(O) 2 R y2 , —N(R y3 )C(O)O(R y2 ), —N(R y3 )C(O)NR y3 R y4 , —N(R y3 )S(O) 2 NR y3 R y4 , G 2b , —(C 1 -C 6  alkylenyl)-OR, —(C 1 -C 6  alkylenyl)-OC(O)R y2 , —(C 1 -C 6  alkylenyl)-OC(O)NR y3 R y4 , —(C 1 -C 6  alkylenyl)-S(O) 2 R y1 , —(C 1 -C 6  alkylenyl)-S(O) 2 NR y3 R y4 , —(C 1 -C 6  alkylenyl)-C(O)R y1 , —(C 1 -C 6  alkylenyl)-C(O)OR y1 , —(C 1 -C 6  alkylenyl)-C(O)NR y3 R y4 , —(C 1 -C 6  alkylenyl)-NR y3 R y4 , —(C 1 -C 6  alkylenyl)-N(R y3 )C(O)R y2 , —(C 1 -C 6  alkylenyl)-N(R y3 )S(O) 2 R y2 , —(C 1 -C 6  alkylenyl)-N(R y3 )C(O)O(R y2 ), —(C 1 -C 6  alkylenyl)-N(R y3 )C(O)NR y3 R y4 , —(C 1 -C 6  alkylenyl)-N(R y3 )S(O) 2 NR y3 R y4 , —(C 1 -C 6  alkylenyl)-CN, or —(C 1 -C 6  alkylenyl)-G 2b ; 
         R y1 , R y3 , and R y4 , at each occurrence, are each independently H, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, G 2b , or —(C 1 -C 6  alkylenyl)-G 2b ; 
         R y2 , at each occurrence, is independently C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, G 2b , or —(C 1 -C 6  alkylenyl)-G 2b ; 
         G 2b , at each occurrence, is independently aryl, heteroaryl, cycloalkyl, cycloalkenyl, or heterocycle; and each G 2b  group is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , —OR z1 , —OC(O)R z2 , —OC(O)NR z3 R z4 , —SR z1 , —S(O) 2 R z1 , —S(O) 2 NR z3 R z4 , —C(O)R z1 , —C(O)OR z1 , —C(O)NR z3 R z4 , —NR z3 R z4 , —N(R z3 )C(O)R z2 , —N(R z3 )S(O) 2 R z2 , —N(R z3 )C(O)O(R z2 ), —N(R z3 )C(O)NR z3 R z4 , —N(R z3 )S(O) 2 NR z3 R z4 , —(C 1 -C 6  alkylenyl)-OR z1 , —(C 1 -C 6  alkylenyl)-OC(O)R z2 , —(C 1 -C 6  alkylenyl)-OC(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-S(O) 2 R z1 , —(C 1 -C 6  alkylenyl)-S(O) 2 NR z3 R z4 , —(C 1 -C 6  alkylenyl)-C(O)R z1 , —(C 1 -C 6  alkylenyl)-C(O)OR z1 , —(C 1 -C 6  alkylenyl)-C(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-NR z3 R z4 , —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)R z2 , —(C 1 -C 6  alkylenyl)-N(R z3 )S(O) 2 R z2 , —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)O(R z2 ), —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-N(R z3 )S(O) 2 NR z3 R z4 , and —(C 1 -C 6  alkylenyl)-CN; 
         R z1 , R z3 , and R z4 , at each occurrence, are each independently H, C 1 -C 6  alkyl, or C 1 -C 6  haloalkyl; and 
         R z2 , at each occurrence, is independently C 1 -C 6  alkyl or C 1 -C 6  haloalkyl. 
       
     
     
         2 . The compound of  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1  is C 1 -C 3  alkyl. 
     
     
         3 . The compound of  claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 2  is H or C 1 -C 3  alkyl. 
     
     
         4 . The compound of  claim 3 , or a pharmaceutically acceptable salt thereof, wherein R 5  is phenyl, pyridinyl, or indolyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , G 2 , —OR a , —OC(O)R b , —OC(O)NR c R d , —SR a , —S(O) 2 R a , —S(O) 2 NR c R d , —C(O)R a , —C(O)OR a , —C(O)NR c R d , —NR c R d , —N(R e )C(O)R b , —N(R e )S(O) 2 R b , —N(R e )C(O)O(R b ), —N(R e )C(O)NR c R d , —N(R e )S(O) 2 NR c R d , —(C 1 -C 6  alkylenyl)-G 2 , —(C 1 -C 6  alkylenyl)-OR a , —(C 1 -C 6  alkylenyl)-OC(O)R b , —(C 1 -C 6  alkylenyl)-OC(O)NR c R d , —(C 1 -C 6  alkylenyl)-S(O) 2 R a , —(C 1 -C 6  alkylenyl)-S(O) 2 NR c R d , —(C 1 -C 6  alkylenyl)-C(O)R a , —(C 1 -C 6  alkylenyl)-C(O)OR a , —(C 1 -C 6  alkylenyl)-C(O)NR c R d , —(C 1 -C 6  alkylenyl)-NR c R d , —(C 1 -C 6  alkylenyl)-N(R e )C(O)R b , —(C 1 -C 6  alkylenyl)-N(R e )S(O) 2 R b , —(C 1 -C 6  alkylenyl)-N(R e )C(O)O(R b ), —(C 1 -C 6  alkylenyl)-N(R e )C(O)NR c R d , —(C 1 -C 6  alkylenyl)-N(R e )S(O) 2 NR c R d , and —(C 1 -C 6  alkylenyl)-CN. 
     
     
         5 . The compound of  claim 3 , or a pharmaceutically acceptable salt thereof, wherein
 R 3  is H, C 1 -C 6  alkyl, C 2 -C 6  alkenyl, halogen, —C(O)R 3a , —C(O)OR 3a , —C(O)NR 3b R 3c , or G 1 ; wherein the C 1 -C 6  alkyl and the C 2 -C 6  alkenyl are each independently unsubstituted or substituted with 1 or 2 substituents independently selected from the group consisting of halogen, G, —OR 3a , and —NR 3b R 3c .   
     
     
         6 . The compound of  claim 4 , or a pharmaceutically acceptable salt thereof, wherein
 R 3  is H, C 1 -C 3  alkyl, C 2 -C 4  alkenyl, halogen, or G 1 ; wherein the C 1 -C 3  alkyl and the C 2 -C 4  alkenyl are each independently unsubstituted or substituted with 1 or 2 substituents independently selected from the group consisting of halogen, —OH, —O(C 1 -C 3  alkyl), —NH 2 , —N(H)(C 1 -C 3  alkyl), or —N(C 1 -C 3  alkyl) 2 .   
     
     
         7 . The compound of  claim 3 , or a pharmaceutically acceptable salt thereof, wherein
 R 3  is H, halogen, unsubstituted C 1 -C 3  alkyl, optionally substituted phenyl, optionally substituted 1,2-oxazolyl, or C 2 -C 4  alkenyl which is substituted with 2 substituents independently selected from the group consisting of halogen and —OH; and   R 5  is phenyl or pyridinyl, each of which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of C 1 -C 3  alkyl, halogen, C 1 -C 3  haloalkyl, —CN, NO 2 , G 2 , —OR a , —S(O) 2 R a , —S(O) 2 NR c R d , —C(O)R a , —C(O)OR a , —C(O)NR c R d , —NR c R d , —N(R e )S(O) 2 R b , —(C 1 -C 3  alkylenyl)-G 2  wherein G 2  is optionally substituted heterocycle, —(C 1 -C 3  alkylenyl)-S(O) 2 R a , —(C 1 -C 3  alkylenyl)-S(O) 2 NR c R d , —(C 1 -C 3  alkylenyl)-NR c R d , and —(C 1 -C 3  alkylenyl)-N(R e )S(O) 2 R b .   
     
     
         8 . The compound of  claim 3 , or a pharmaceutically acceptable salt thereof, wherein
 R 1  is C 1 -C 3  alkyl;   R 2  is H or C 1 -C 3  alkyl;   R 3  is H, unsubstituted C 1 -C 3  alkyl, or halogen;   R 4  is H, C 1 -C 3  alkyl, or halogen; and   R 5  is phenyl or pyridinyl; each of which is substituted with 1, 2, or 3 substituents, wherein one substituent is selected from the group consisting of —OR a  and —NR c R d , and the other optional substituents are selected from the group consisting of C 1 -C 3  alkyl, halogen, C 1 -C 3  haloalkyl, —S(O) 2 R a , —S(O) 2 NR c R d , —N(R e )S(O) 2 R b , —(C 1 -C 3  alkylenyl)-G 2  wherein G 2  is optionally substituted heterocycle, —(C 1 -C 3  alkylenyl)-S(O) 2 R a , —(C 1 -C 3  alkylenyl)-S(O) 2 NR c R d , —(C 1 -C 3  alkylenyl)-NR c R d , and —(C 1 -C 3  alkylenyl)-N(R e )S(O) 2 R b .   
     
     
         9 . The compound of  claim 3 , or a pharmaceutically acceptable salt thereof, wherein
 R 3  is H, unsubstituted C 1 -C 3  alkyl, or halogen;   R 4  is H, C 1 -C 3  alkyl, or halogen; and   R 5  is indolyl substituted with 1 or 2 substituents independently selected from the group consisting of —OR a , —C(O)OR a , and —C(O)NR c R d .   
     
     
         10 . The compound of  claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5  is represented by the following formula: 
       
         
           
           
               
               
           
         
         wherein 
         A 1  is C(R 7 ), A 2  is C(R 8 ), A 3  is C(R 9 ), and A 4  is C(R 10 ); or 
         A 1  is N, A 2  is C(R 8 ), A 3  is C(R 9 ), and A 4  is C(R 10 ); or 
         A 1  is C(R 7 ), A 2  is N, A 3  is C(R 9 ), and A 4  is C(R 10 ); or 
         A 1  is C(R 7 ), A 2  is C(R 8 ), A 3  is N, and A 4  is C(R 10 ); or 
         A 1  is C(R 7 ), A 2  is C(R 8 ), A 3  is C(R 9 ), and A 4  is N; 
         R 6  is halogen, —OR a , or —NR c R d ; 
         R 7  is H, C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , or C 3 -C 6  cycloalkyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halogen, C 1 -C 3  alkyl, and CN; 
         R 10  is H, C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, or NO 2 ; 
         R 8  is H, halogen, —OR a , —NR c R d , —C(O)R a , —C(O)NR c R d , G 2 , —(C 1 -C 6  alkylenyl)-G 2 , or —(C 1 -C 6  alkylenyl)-NR c R d ; 
         R 9  is H, halogen, —CN, C 1 -C 6  haloalkyl, —N(R e )S(O) 2 R b , —S(O) 2 R a , —S(O) 2 NR c R d , —(C 1 -C 6  alkylenyl)-G 2  wherein G 2  is optionally substituted heterocycle, —(C 1 -C 6  alkylenyl)-S(O) 2 R a , —(C 1 -C 6  alkylenyl)-S(O) 2 NR c R d , —(C 1 -C 6  alkylenyl)-NR c R d , or —(C 1 -C 6  alkylenyl)-N(R e )S(O) 2 R b ; 
         R a , R c , R d , and R e , at each occurrence, are each independently H, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, C 1 -C 6  haloalkyl, G 2 , or C 1 -C 6  alkyl wherein the C 1 -C 6  alkyl is optionally substituted with one substituent selected from the group consisting of —OR y1 , —NR y3 R y4 , —C(O)OR y1 , —C(O)NR y3 R y4 , —S(O) 2 R y1 , —S(O) 2 NR y3 R y4 , and G 2 ; 
         R b , at each occurrence, is independently C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, C 1 -C 6  haloalkyl, G 2 , or C 1 -C 6  alkyl wherein the C 1 -C 6  alkyl is optionally substituted with one substituent selected from the group consisting of —OR y1 , —NR y3 R y4 , —C(O)OR y1 , —C(O)NR y3 R y4 , —S(O) 2 R y1 , —S(O) 2 NR y3 R y4 , and G 2 ; 
         G 2 , at each occurrence, are each independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; and each G 2  group is optionally substituted with 1, 2, 3, 4, or 5 R 2g  groups; 
         R 2g , at each occurrence, is independently C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , —OR y1 , —OC(O)R y2 , —OC(O)NR y3 R y4 , —SR y1 , —S(O) 2 R y1 , —S(O) 2 NR y3 R y4 , —C(O)R y1 , —C(O)OR y1 , —C(O)NR y3 R y4 , —NR y3 R y4 , —N(R y3 )C(O)R y2 , —N(R y3 )S(O) 2 R y2 , —N(R y3 )C(O)O(R y2 ), —N(R y3 )C(O)NR y3 R y4 , —N(R y3 )S(O) 2 NR y3 R y4 , G 2b , —(C 1 -C 6  alkylenyl)-OR y1 , —(C 1 -C 6  alkylenyl)-OC(O)R y2 , —(C 1 -C 6  alkylenyl)-OC(O)NR y3 R y4 , —(C 1 -C 6  alkylenyl)-S(O) 2 R y1 , —(C 1 -C 6  alkylenyl)-S(O) 2 NR y3 R y4 , —(C 1 -C 6  alkylenyl)-C(O)R y1 , —(C 1 -C 6  alkylenyl)-C(O)OR y1 , —(C 1 -C 6  alkylenyl)-C(O)NR y3 R y4 , —(C 1 -C 6  alkylenyl)-NR y3 R y4 , —(C 1 -C 6  alkylenyl)-N(R y3 )C(O)R y2 , —(C 1 -C 6  alkylenyl)-N(R y3 )S(O) 2 R y2 , —(C 1 -C 6  alkylenyl)-N(R y3 )C(O)O(R y2 ), —(C 1 -C 6  alkylenyl)-N(R y3 )C(O)NR y3 R y4 , —(C 1 -C 6  alkylenyl)-N(R y3 )S(O) 2 NR y3 R y4 , —(C 1 -C 6  alkylenyl)-CN, or —(C 1 -C 6  alkylenyl)-G 2b ; 
         R y1 , R y3 , and R y4 , at each occurrence, are each independently H, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, G 2b , or —(C 1 -C 6  alkylenyl)-G 2b ; 
         R y2 , at each occurrence, is independently C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, G 2b , or —(C 1 -C 6  alkylenyl)-G 2b ; 
         G 2b , at each occurrence, is independently aryl, heteroaryl, cycloalkyl, cycloalkenyl, or heterocycle; and each G 2b  group is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , —OR z1 , —OC(O)R z2 , —OC(O)NR z3 R z4 , —SR z1 , —S(O) 2 R z1 , —S(O) 2 NR z3 R z4 , —C(O)R z1 , —C(O)OR z1 , —C(O)NR z3 R z4 , —NR z3 R z4 , —N(R z3 )C(O)R z2 , —N(R z3 )S(O) 2 R z2 , —N(R z3 )C(O)O(R z2 ), —N(R z3 )C(O)NR z3 R z4 , —N(R z3 )S(O) 2 NR z3 R z4 , —(C 1 -C 6  alkylenyl)-OR z1 , —(C 1 -C 6  alkylenyl)-OC(O)R z2 , —(C 1 -C 6  alkylenyl)-OC(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-S(O) 2 R z1 , —(C 1 -C 6  alkylenyl)-S(O) 2 NR z3 R z4 , —(C 1 -C 6  alkylenyl)-C(O)R z1 , —(C 1 -C 6  alkylenyl)-C(O)OR z1 , —(C 1 -C 6  alkylenyl)-C(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-NR z3 R z4 , —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)R z2 , —(C 1 -C 6  alkylenyl)-N(R z3 )S(O) 2 R z2 , —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)O(R z2 ), —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-N(R z3 )S(O) 2 NR z3 R z4 , and —(C 1 -C 6  alkylenyl)-CN; 
         R z1 , R z3 , and R z4 , at each occurrence, are each independently H, C 1 -C 6  alkyl, or C 1 -C 6  haloalkyl; and 
         R z2 , at each occurrence, is independently C 1 -C 6  alkyl or C 1 -C 6  haloalkyl. 
       
     
     
         11 . The compound of  claim 10 , or a pharmaceutically acceptable salt thereof, wherein
 R 1  is methyl; and   R 2  is H or methyl.   
     
     
         12 . The compound of  claim 11 , or a pharmaceutically acceptable salt thereof, wherein
 R 2  is H;   R 3  is H, unsubstituted C 1 -C 3  alkyl, or halogen; and   R 4  is H, C 1 -C 3  alkyl, or halogen.   
     
     
         13 . The compound of  claim 12 , or a pharmaceutically acceptable salt thereof wherein
 A 1  is C(R 7 ), A 2  is C(R 8 ), A 3  is C(R 9 ), and A 4  is C(R 10 ); or   A 1  is N, A 2  is C(R 8 ), A 3  is C(R 9 ), and A 4  is C(R 10 ).   
     
     
         14 . The compound of  claim 13 , or a pharmaceutically acceptable salt thereof wherein
 R 7  is H;   R 8  is H or halogen; and   R 10  is H or C 1 -C 6  alkyl.   
     
     
         15 . The compound of  claim 14 , or a pharmaceutically acceptable salt thereof wherein
 R 6  is —OR a  or —NR c R d , wherein
 R a  and R d  are each independently C 1 -C 6  haloalkyl, G 2 , or C 1 -C 6  alkyl wherein the C 1 -C 6  alkyl is optionally substituted with one G 2  group; and 
 R c  is H or unsubstituted C 1 -C 6  alkyl; and 
   R 9  is —N(R e )S(O) 2 R b , —S(O) 2 R a , —S(O) 2 NR c R d , —(C 1 -C 6  alkylenyl)-G 2  wherein G 2  is optionally substituted heterocycle, —(C 1 -C 6  alkylenyl)-S(O) 2 R a , —(C 1 -C 6  alkylenyl)-S(O) 2 NR c R d , —(C 1 -C 6  alkylenyl)-NR c R d , or —(C 1 -C 6  alkylenyl)-N(R e )S(O) 2 R b .   
     
     
         16 . The compound of  claim 14 , or a pharmaceutically acceptable salt thereof wherein
 R 6  is —OR a  or —NR c R d , wherein
 R a  and Rd are each independently C 1 -C 6  haloalkyl or unsubstituted C 1 -C 6  alkyl; and 
 R c  is H or unsubstituted C 1 -C 3  alkyl; and 
   R 9  is —S(O) 2 R a  or —(CH 2 )—SO 2 R a , wherein R a , at each occurrence, is independently unsubstituted C 1 -C 3  alkyl.   
     
     
         17 . The compound of  claim 14 , or a pharmaceutically acceptable salt thereof wherein
 R 6  is —OR a  or —NR c R d , wherein
 R a  is G 2  or C 1 -C 3  alkyl wherein the C 1 -C 3  alkyl is substituted with one G 2  group; and G 2  is aryl, C 4 -C 6  heterocycle, C 3 -C 6  cycloalkyl, C 5 -C 6  heteroaryl, or adamantyl, each of which is optionally substituted; 
 R c  is H or unsubstituted C 1 -C 3  alkyl; and 
 R d  is optionally substituted phenyl or C 1 -C 3  alkyl wherein the C 1 -C 3  alkyl is substituted with one G 2  group; and G 2  is phenyl, C 3 -C 6  cycloalkyl, or bicyclo[2.2.1]heptyl, each of which is optionally substituted; and 
   R 9  is —N(R e )S(O) 2 R b , —S(O) 2 R a , —S(O) 2 NR c R d , —(C 1 -C 3  alkylenyl)-G 2  wherein G 2  is optionally substituted C 4 -C 6  heterocycle; —(C 1 -C 3  alkylenyl)-S(O) 2 R a , —(C 1 -C 3  alkylenyl)-S(O) 2 NR c R d , —(C 1 -C 3  alkylenyl)-NR c R d , or —(C 1 -C 3  alkylenyl)-N(R e )S(O) 2 R b ; wherein
 R a  and R b  are each independently C 1 -C 6  haloalkyl, G 2 , or C 1 -C 6  alkyl wherein the C 1 -C 6  alkyl is optionally substituted with one G 2  group, and G 2  is phenyl, C 3 -C 6  cycloalkyl, C 5 -C 6  heteroaryl, or C 4 -C 6  heterocycle, each of which is optionally substituted; 
 R e  and R c  are each independently H or unsubstituted C 1 -C 3  alkyl; and 
 R d  is H, C 1 -C 6  haloalkyl, G 2 , or C 1 -C 6  alkyl wherein the C 1 -C 6  alkyl is optionally substituted with one G 2  group, and G 2  is phenyl, C 3 -C 6  cycloalkyl, C 5 -C 6  heteroaryl, or C 4 -C 6  heterocycle, each of which is optionally substituted. 
   
     
     
         18 . The compound of  claim 14 , or a pharmaceutically acceptable salt thereof wherein
 R 6  is —OR a ; wherein
 R a  is G 2 , and 
 G 2  is optionally substituted phenyl or optionally substituted C 3 -C 6  cycloalkyl; and 
   R 9  is —N(R e )S(O) 2 R b , —S(O) 2 R a , —(C 1 -C 3  alkylenyl)-S(O) 2 R a , —(C 1 -C 3  alkylenyl)-S(O) 2 NR c R d , or —(C 1 -C 3  alkylenyl)-N(R e )S(O) 2 R b ; wherein
 R a  is unsubstituted C 1 -C 3  alkyl or optionally substituted C 4 -C 6  heterocycle, 
 R b  is unsubstituted C 1 -C 3  alkyl or optionally substituted benzyl; 
 R c  is H or unsubstituted C 1 -C 3  alkyl; 
 R d  is H or unsubstituted C 1 -C 3  alkyl; and 
 R e  is H. 
   
     
     
         19 . The compound of  claim 14 , or a pharmaceutically acceptable salt thereof wherein
 R 3  is H;   R 4  is H;   R 6  is —OR a ; wherein
 R a  is G 2 , and 
 G 2  is phenyl substituted with 1 or 2 halogen; and 
   R 9  is —N(R e )S(O) 2 R b , —S(O) 2 R a , or —(CH 2 )—S(O) 2 R a , wherein
 R a  and R b  are each independently unsubstituted C 1 -C 3  alkyl, and 
 R e  is H. 
   
     
     
         20 . The compound of  claim 14 , or a pharmaceutically acceptable salt thereof, wherein
 R 6  is —NR c R d , wherein
 R c  is H or unsubstituted C 1 -C 3  alkyl; and 
 R d  is optionally substituted phenyl or C 1 -C 3  alkyl wherein the C 1 -C 3  alkyl is substituted with one G 2  group, wherein G 2  is optionally substituted C 3 -C 6  cycloalkyl, and 
   R 9  is —N(R e )S(O) 2 R b , —S(O) 2 R a , —(C 1 -C 3  alkylenyl)-S(O) 2 R a , —(C 1 -C 3  alkylenyl)-S(O) 2 NR c R d , or —(C 1 -C 3  alkylenyl)-N(R e )S(O) 2 R b ; wherein
 R a  is unsubstituted C 1 -C 3  alkyl or optionally substituted C 4 -C 6  heterocycle, 
 R b  is unsubstituted C 1 -C 3  alkyl or optionally substituted benzyl; 
 R c  is H or unsubstituted C 1 -C 3  alkyl; 
 R d  is H or unsubstituted C 1 -C 3  alkyl; and 
 R e  is H. 
   
     
     
         21 . The compound of  claim 14 , or a pharmaceutically acceptable salt thereof, wherein
 R 3  is H,   R 4  is H,   R 6  is —NR c R d , wherein
 R c  is H or methyl; and 
 R d  is phenyl substituted with 1 or 2 halogen, or R d  is C 1 -C 3  alkyl wherein the C 1 -C 3  alkyl is substituted with one G 2  group, and G 2  is optionally substituted cyclopropyl, and 
   R 9  is —(CH 2 )—S(O) 2 R a ; wherein R a  is unsubstituted C 1 -C 3  alkyl.   
     
     
         22 . The compound of  claim 1  or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
 1-methyl-3-(2-phenoxyphenyl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]propane-2-sulfonamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]ethanesulfonamide; 
 N-[4-(4-chlorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]ethanesulfonamide; 
 N-{4-[(trans-4-methoxycyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide; 
 N-[3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(tetrahydro-2H-pyran-4-yloxy)phenyl]ethanesulfonamide; 
 N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide; 
 N-{4-[(cis-4-methoxycyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide; 
 N-[3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(oxetan-3-yloxy)phenyl]ethanesulfonamide; 
 N-[4-(2,4-difluorophenoxy)-2-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; 
 N-[2-(2,4-difluorophenoxy)-4-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; 
 N-[2,4-bis(2,4-difluorophenoxy)-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; 
 N-[4-(cyclopropylmethoxy)-2-methyl-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]ethanesulfonamide; 
 N-[4-(4-fluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]ethanesulfonamide; 
 N-[4-(4-cyanophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; 
 3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-[5-(methylsulfonyl)-2-phenoxyphenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(3,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-methoxy-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydrofuran-3-yloxy)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydrofuran-3-ylmethoxy)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-4-yloxy)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(4,4-difluorocyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-3-yloxy)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,2-dimethylpropoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(cyclobutylmethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-{2-[1-methylcyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-[5-(methylsulfonyl)-2-(oxetan-3-ylmethoxy)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-[5-(methylsulfonyl)-2-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(cis-4-hydroxycyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(trans-4-hydroxycyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2-cyclopentylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2-cyclohexylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-[5-(methylsulfonyl)-2-(2-phenylethoxy)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,3-dihydro-1H-inden-2-yloxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-{5-(methylsulfonyl)-2-[2-(thiophen-2-yl)ethoxy]phenyl}-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(3,3-dimethylbutoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(4, 4-difluorocyclohexyl)methoxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(methylsulfonyl)phenyl}-1,6-dimethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(cyclopropylmethyl)(methyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 4-({[2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-(methylsulfonyl)phenyl]amino}methyl)benzonitrile; 
 3-{2-[(cyclohexylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(4-chlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(cyclopropylmethoxy)-6-methylphenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzenesulfonamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[2-(ethylsulfonyl)propan-2-yl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[1-(ethylsulfonyl)ethyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(1R)-1-(ethylsulfonyl)ethyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(1S)-1-(ethylsulfonyl)ethyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(phenylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)pyridin-3-yl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]pyridin-3-yl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(4-fluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(4-tert-butylphenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-[5-(methylsulfonyl)-2-(naphthalen-2-yloxy)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-[5-(methylsulfonyl)-2-(2,2,3,3,3-pentafluoropropoxy)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-[5-(methylsulfonyl)-2-{2-[tricyclo[3.3.1.1 3,7 ]dec-1-yl]ethoxy}phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(3-cyclopentylpropoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(1-acetylpiperidin-4-yl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(cyclopentylmethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-methyl-3-{5-(methylsulfonyl)-2-[(2,2,2-trifluoroethyl)amino]phenyl}-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(2,2,3,3,4,4,4-heptafluorobutyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-{[(1S,4R)-bicyclo[2.2.1]hept-2-ylmethyl]amino}-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(2-cyclopentylethyl)amino]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2-chloro-4-methylphenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[5-(ethylsulfonyl)-2-(pyridin-4-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(4,6-dimethylpyridin-3-yl)oxy]-5-(ethylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(3,4-dichlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{5-(ethylsulfonyl)-2-[4-(trifluoromethyl)phenoxy]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 4-[4-(ethylsulfonyl)-2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenoxy]benzonitrile; 
 3-[2-(4-chloro-3-ethylphenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 4-[4-(ethylsulfonyl)-2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenoxy]-3-methoxybenzonitrile; 
 3-[5-(ethylsulfonyl)-2-(pyridin-3-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,4-dichlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 2-[4-(ethylsulfonyl)-2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenoxy]benzonitrile; 
 3-[2-(2,3-dichlorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2-chloro-4-methoxyphenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{5-(ethylsulfonyl)-2-[(6-methylpyrazin-2-yl)oxy]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[5-(ethylsulfonyl)-2-(pyridazin-4-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[5-(ethylsulfonyl)-2-(pyrimidin-5-yloxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{5-(ethylsulfonyl)-2-[(3-methylpyrazin-2-yl)oxy]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{5-(ethylsulfonyl)-2-[(1,3,5-trimethyl-1H-pyrazol-4-yl)oxy]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 5-chloro-3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-ethyl-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3,5-bis{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(morpholin-4-ylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; 
 3-[2-(cyclopropylmethoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[6-(cyclopropylmethoxy)-1H-indol-7-yl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 ethyl 5-(cyclopropylmethoxy)-4-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indole-2-carboxylate; 
 1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-N-methylmethanesulfonamide; 
 1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-N,N-dimethylmethanesulfonamide; 
 N-cyclohexyl-1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(piperidin-1-ylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-N-(1,3-thiazol-2-yl)methanesulfonamide; 
 3-[2-(2,4-difluorophenoxy)-5-(piperazin-1-ylmethyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]ethanesulfonamide; 
 5-(cyclopropylmethoxy)-N-methyl-4-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indole-2-carboxamide; 
 4-chloro-3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 4-chloro-3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(cyclopropylmethyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{5-[(4-aminopiperidin-1-yl)methyl]-2-(2,4-difluorophenoxy)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(piperidin-4-ylamino)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,4-difluorophenoxy)-5-{[4-(dimethylamino)piperidin-1-yl]methyl}phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,4-difluorophenoxy)-5-{[(3,3-dimethylbutyl)amino]methyl}phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(4-methoxypiperidin-1-yl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(4-methylpiperazin-1-yl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,4-difluorophenoxy)-5-{[(3-methylbutyl)amino]methyl}phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[5-{[(cyclopropylmethyl)amino]methyl}-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,4-difluorophenoxy)-5-{[(1H-imidazol-4-ylmethyl)amino]methyl}phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[5-(chloromethyl)-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(4-fluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1,4-dimethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2-cyclopropylethoxy)-5-(methylsulfonyl)phenyl]-1,4-dimethyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(cyclopropylmethoxy)-5-[(3,3-difluoroazetidin-1-yl)sulfonyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 5-[(1Z)-2-chloro-4-hydroxybut-1-en-1-yl]-3-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,4-difluorophenoxy)-5-{[(furan-3-ylmethyl)amino]methyl}phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[5-{[(2-cyclopentylethyl)amino]methyl}-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,4-difluorophenoxy)-5-{[4-(trifluoromethyl)piperidin-1-yl]methyl}phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]-2-methoxybenzenesulfonamide; 
 1-(4-chlorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]methanesulfonamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]-1-(4-methylphenyl)methanesulfonamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]-1-[4-(trifluoromethyl)phenyl]methanesulfonamide; 
 1-(4-cyanophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]methanesulfonamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]-2,2,2-trifluoroethanesulfonamide; 
 3-[5-(aminomethyl)-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]cyclopentanesulfonamide; 
 2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]thiophene-3-sulfonamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]-5-methyl-1,2-oxazole-4-sulfonamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]-3,5-dimethyl-1,2-oxazole-4-sulfonamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)benzyl]benzenesulfonamide; 
 3-{2-[(cyclopropylmethyl)amino]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-chloro-5-[(methylsulfonyl)methyl]pyridin-3-yl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-{[trans-4-(dimethylamino)cyclohexyl]oxy}-5-(pyrrolidin-1-ylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{5-fluoro-2-[(4-fluorophenyl)amino]pyridin-3-yl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[5-amino-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-4-methylpentanamide; 
 2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]benzamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-2-(2-methoxyphenyl)acetamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]pyridine-2-carboxamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-5-methylpyrazine-2-carboxamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-3-phenylpropanamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-4-phenoxybutanamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-2-(3-phenoxyphenyl)acetamide; 
 4-(acetylamino)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]benzamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-4-(phenoxymethyl)benzamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-2-oxo-1-phenylpyrrolidine-3-carboxamide; 
 2-(1,2-benzoxazol-3-yl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]acetamide; 
 2-(5-chloro-2-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]acetamide; 
 2-(4-chloro-2-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]acetamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-2-(6-methylpyridin-3-yl)acetamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-2-(3,4-dihydro-2H-chromen-6-yl)acetamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-2-(2-methyl-1,3-thiazol-5-yl)acetamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-2-(1,5-dimethyl-1H-pyrazol-3-yl)acetamide; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-2-[4-(2-fluorophenyl)-1H-pyrazol-1-yl]acetamide; 
 methyl (2E)-3-[(4-fluorophenyl) {2-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-4-[(methylsulfonyl)methyl]phenyl}amino]prop-2-enoate; 
 4-({[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]amino}methyl)benzonitrile; 
 3-[2-(2,4-difluorophenoxy)-5-{[3-(4-methoxyphenoxy)benzyl]amino}phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[2-(2,4-difluorophenoxy)-5-{[(3-methylpyridin-2-yl)methyl]amino}phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[5-{[4-(benzyloxy)benzyl]amino}-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[5-{[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino}-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-({[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]amino}methyl)benzonitrile; 
 3-{2-(2,4-difluorophenoxy)-5-[(4-phenoxybenzyl)amino]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(3,3-dimethylbutyl)amino]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{5-[(2,6-difluorobenzyl)amino]-2-(2,4-difluorophenoxy)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-ylmethyl)amino]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-[5-{[2-(benzyloxy)-3-methoxybenzyl]amino}-2-(2,4-difluorophenoxy)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 2-({[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]amino}methyl)benzonitrile; 
 3-{2-(2,4-difluorophenoxy)-5-[(quinolin-4-ylmethyl)amino]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-1-phenylmethanesulfonamide; 
 1-(2-chloro-5-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; 
 N-{4-(2,4-difluorophenoxy)-3-[1-methyl-5-(morpholin-4-ylmethyl)-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide; 
 N-{4-(2,4-difluorophenoxy)-3-[1-methyl-7-oxo-5-(piperidin-4-yl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide; 
 N-[6-(2,4-difluorophenoxy)-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-3-yl]ethanesulfonamide; 
 N-[3-{5-[1-(cyclopropylcarbonyl)piperidin-4-yl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl}-4-(2,4-difluorophenoxy)phenyl]ethanesulfonamide; 
 N-[4-(2,4-difluorophenoxy)-3-{5-[1-(ethylsulfonyl)piperidin-4-yl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl}phenyl]ethanesulfonamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-[3-(1H-imidazol-1-yl)propyl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-[2-(dimethylamino)ethyl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 N-(cyanomethyl)-3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-(3-hydroxypropyl)-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 N-{4-(2,4-difluorophenoxy)-3-[1-methyl-5-(morpholin-4-ylcarbonyl)-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo-N-(pyridin-3-ylmethyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 N-{4-(2,4-difluorophenoxy)-3-[1-methyl-7-oxo-5-(pyrrolidin-1-ylcarbonyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl]phenyl}ethanesulfonamide; 
 N-[4-(2,4-difluorophenoxy)-3-{5-[(4-hydroxypiperidin-1-yl)carbonyl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl}phenyl]ethanesulfonamide; 
 N-(cyclopentylmethyl)-3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-N-[2-(morpholin-4-yl)ethyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-N-[2-(4-methylpiperazin-1-yl)ethyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo-N-[2-(piperidin-1-yl)ethyl]-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo-N-(tetrahydrofuran-3-ylmethyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N,1-dimethyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-N-(furan-3-ylmethyl)-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 3-{3-cyclopropyl-2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; and 
 1-methyl-3-{5-[(methylsulfonyl)methyl]-2-(pyridin-2-ylamino)phenyl}-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one. 
 
     
     
         23 . The compound of  claim 11  or a pharmaceutically acceptable salt wherein
 R 2  is H; 
 R 3  is —C(O)R 3a , —C(O)NR 3b R 3c , C 4 -C 6  heterocycle, or C 1 -C 3  alkyl which is substituted with C 4 -C 6  heterocycle; wherein each of the C 4 -C 6  heterocycle moieties is optionally substituted with 1, 2, 3, 4, or 5 R 1g ; 
 R 3a  is C 4 -C 6  heterocycle which is optionally substituted with 1, 2, 3, 4, or 5 R 1g ; 
 R 3b  is H or C 1 -C 6  alkyl; 
 R 3c  is H, C 1 -C 6  alkyl, —(C 1 -C 6  alkylenyl)-OR z1 , —(C 1 -C 6  alkylenyl)-NR z3 R z4 , —(C 1 -C 6  alkylenyl)-CN, or —(C 1 -C 6  alkylenyl)-G 1 ; wherein G 1  is C 4 -C 6  heterocycle, C 5 -C 6  heteroaryl, C 3 -C 6  cycloalkyl, or phenyl; each of which is optionally substituted with 1, 2, 3, 4, or 5 R 1g ; 
 R 6  is —OR a  or —NR c R d ; wherein
 R a  and R d  are each independently G 2  or C 1 -C 6  alkyl substituted with a G 2  group; wherein G 2  is phenyl, C 3 -C 6  cycloalkyl, C 4 -C 6  heterocycle, or C 5 -C 6  heteroaryl; each of which is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , —OR y1 , —OC(O)R y2 , —OC(O)NR y3 R y4 , —SR y1 , —S(O) 2 R y1 , —S(O) 2 NR y3 R y4 , —C(O)R y1 , —C(O)OR y1 , —C(O)NR y3 R y4 , —NR y3 R y4 , —N(R y3 )C(O)R y2 , —N(R y3 )S(O) 2 R y2 , —N(R y3 )C(O)O(R y2 ), —N(R y3 )C(O)NR y3 R y4 , and —N(R y3 )S(O) 2 NR y3 R y4 ; 
 R c  is hydrogen or unsubstituted C 1 -C 6  alkyl; 
 R y1 , R y3 , and R y4 , at each occurrence, are each independently H, C 1 -C 6  alkyl, or C 1 -C 6  haloalkyl; and 
 R y2 , at each occurrence, is independently C 1 -C 6  alkyl or C 1 -C 6  haloalkyl; and 
 
 R 9  is H, halogen, —CN, C 1 -C 6  haloalkyl, —N(R e )S(O) 2 R b , —S(O) 2 R a , —S(O) 2 NR c R d , —(C 1 -C 6  alkylenyl)-S(O) 2 R a , —(C 1 -C 6  alkylenyl)-S(O) 2 NR c R d , —(C 1 -C 6  alkylenyl)-NR c R d , or —(C 1 -C 6  alkylenyl)-N(R e )S(O) 2 R b ; wherein
 R c , R d , and R e , at each occurrence, are each independently H or unsubstituted C 1 -C 6  alkyl; and 
 R a  and R b , at each occurrence, is independently C 1 -C 6  haloalkyl, or unsubstituted C 1 -C 6  alkyl. 
 
 
     
     
         24 . The compound of  claim 23  or a pharmaceutically acceptable salt wherein
 R 3  is —C(O)R 3a  or —C(O)NR 3b R 3c ; 
 A 1  is C(R 7 ), A 2  is C(R 8 ), A 3  is C(R 9 ), and A 4  is C(R 10 ); or 
 A 1  is N, A 2  is C(R 8 ), A 3  is C(R 9 ), and A 4  is C(R 10 ); 
 R 6  is —OR a  or —NR c R d ; wherein
 R a  and R d  are each independently phenyl, pyridinyl, or C 1 -C 3  alkyl substituted with a C 3 -C 6  cycloalkyl; wherein the phenyl, pyridinyl, and the C 3 -C 6  cycloalkyl are optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , —OR y1 , —OC(O)R y2 , —OC(O)NR y3 R y4 , —SR y1 , —S(O) 2 R y1 , —S(O) 2 NR y3 R y4 , —C(O)R y1 , —C(O)OR y1 , —C(O)NR y3 R y4 , —NR y3 R y4 , —N(R y3 )C(O)R y2 , —N(R y3 )S(O) 2 R y2 , —N(R y3 )C(O)O(R y2 ), —N(R y3 )C(O)NR y3 R y4 , and —N(R y3 )S(O) 2 NR y3 R y4 ; 
 R c  is hydrogen or unsubstituted C 1 -C 3  alkyl; 
 R y1 , R y3 , and R y4 , at each occurrence, are each independently H, C 1 -C 6  alkyl, or C 1 -C 6  haloalkyl; and 
 R y2 , at each occurrence, is independently C 1 -C 6  alkyl or C 1 -C 6  haloalkyl; 
 
 R 7  is H; 
 R 8  is H or halogen; 
 R 10  is H or C 1 -C 6  alkyl; and 
 R 9  is —N(R e )S(O) 2 R b  or —(C 1 -C 6  alkylenyl)-S(O) 2 R a ; wherein
 R e  is H or unsubstituted C 1 -C 3  alkyl; and 
 R a  and R b , are independently C 1 -C 3  alkyl. 
 
 
     
     
         25 . A compound of formula (I) or a pharmaceutically acceptable salt thereof, 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is H, C 1 -C 3  alkyl, or C 1 -C 3  haloalkyl; 
         R 2  is H, C 1 -C 3  alkyl, or C 1 -C 3  haloalkyl; 
         R 3  is H, C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, —OR 3a , —NR 3b R 3c , —N(R 3b )C(O)R 3d , —N(R 3b )C(O)NR 3b R 3c , —N(R 3b )S(O) 2 NR 3b R 3c , —C(O)R 3a , —C(O)OR 3a , —C(O)NR 3b R 3c , —S(O)R 3d , —S(O) 2 R 3a , —S(O) 2 NR 3b R 3c , or G 1 ; wherein the C 1 -C 6  alkyl, C 2 -C 6  alkenyl, and C 2 -C 6  alkynyl are each independently unsubstituted or substituted with 1 or 2 substituents independently selected from the group consisting of halogen, G 1 , —OR 3a , and —NR 3b R 3c ; 
         R 3a , R 3b , and R 3c , at each occurrence, are each independently H, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, G 1 , or —(C 1 -C 6  alkylenyl)-G 1 ; 
         R 3d , at each occurrence, is independently C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, G 1 , or —(C 1 -C 6  alkylenyl)-G 1 ; 
         G 1 , at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; and each G 1  is optionally substituted with 1, 2, 3, 4, or 5 R 1g  groups; 
         R 4  is H, C 1 -C 6  alkyl, halogen, or C 1 -C 6  haloalkyl; 
         R 5  is a monocyclic or bicyclic ring selected from the group consisting of aryl and heteroaryl; each of which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , G 2 , —OR a , —OC(O)R b , —OC(O)NR c R d , —SR a , —S(O) 2 R a , —S(O) 2 NR c R d , —C(O)R a , —C(O)OR a , —C(O)NR c R d , —NR c R d , —N(R e )C(O)R b , —N(R e )S(O) 2 R b , —N(R e )C(O)O(R b ), —N(R e )C(O)NR c R d , —N(R e )S(O) 2 NR c R d , —(C 1 -C 6  alkylenyl)-G 2 , —(C 1 -C 6  alkylenyl)-OR a , —(C 1 -C 6  alkylenyl)-OC(O)R b , —(C 1 -C 6  alkylenyl)-OC(O)NR c R d , —(C 1 -C 6  alkylenyl)-S(O) 2 R a , —(C 1 -C 6  alkylenyl)-S(O) 2 NR c R d , —(C 1 -C 6  alkylenyl)-C(O)R a , —(C 1 -C 6  alkylenyl)-C(O)OR a , —(C 1 -C 6  alkylenyl)-C(O)NR c R d , —(C 1 -C 6  alkylenyl)-NR c R d , —(C 1 -C 6  alkylenyl)-N(R e )C(O)R b , —(C 1 -C 6  alkylenyl)-N(R e )S(O) 2 R b , —(C 1 -C 6  alkylenyl)-N(R e )C(O)O(R b ), —(C 1 -C 6  alkylenyl)-N(R e )C(O)NR c R d , —(C 1 -C 6  alkylenyl)-N(R e )S(O) 2 NR c R d , and —(C 1 -C 6  alkylenyl)-CN; 
         R a , R c , R d , and R e , at each occurrence, are each independently H, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, C 1 -C 6  haloalkyl, G 2 , or C 1 -C 6  alkyl wherein the C 1 -C 6  alkyl is optionally substituted with one substituent selected from the group consisting of —OR y1 , —NR y3 R y4 , —C(O)OR y1 , —C(O)NR y3 R y4 , —S(O) 2 R y1 , —S(O) 2 NR y3 R y4 , and G 2 ; 
         R b , at each occurrence, is independently C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, C 1 -C 6  haloalkyl, G 2 , or C 1 -C 6  alkyl wherein the C 1 -C 6  alkyl is optionally substituted with one substituent selected from the group consisting of —OR y1 , —NR y3 R y4 , —C(O)OR y1 , —C(O)NR y3 R y4 , —S(O) 2 R y1 , —S(O) 2 NR y3 R y4 , and G 2 ; 
         G 2 , at each occurrence, are each independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; and each G 2  group is optionally substituted with 1, 2, 3, 4, or 5 R 2g  groups; 
         R 1g , at each occurrence, is independently C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , —OR z1 , —OC(O)R z2 , —OC(O)NR z3 R z4 , —SR z1 , —S(O) 2 R z1 , —S(O) 2 NR z3 R z4 , —C(O)R z1 , —C(O)OR z1 , —C(O)NR z3 R z4 , —NR z3 R z4 , —N(R z3 )C(O)R z2 , —N(R z3 )S(O) 2 R z2 , —N(R z3 )C(O)O(R z2 ), —N(R z3 )C(O)NR z3 R z4 , —N(R z3 )S(O) 2 NR z3 R 4 , —(C 1 -C 6  alkylenyl)-OR z1 , —(C 1 -C 6  alkylenyl)-OC(O)R z2 , —(C 1 -C 6  alkylenyl)-OC(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-S(O) 2 R z1 , —(C 1 -C 6  alkylenyl)-S(O) 2 NR z3 R z4 , —(C 1 -C 6  alkylenyl)-C(O)R z1 , —(C 1 -C 6  alkylenyl)-C(O)OR z1 , —(C 1 -C 6  alkylenyl)-C(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-NR z3 R z4 , —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)R z2 , —(C 1 -C 6  alkylenyl)-N(R z3 )S(O) 2 R z2 , —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)O(R z2 ), —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-N(R z3 )S(O) 2 NR z3 R z4 , —(C 1 -C 6  alkylenyl)-CN, or —O(phenyl) wherein the phenyl moiety is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of C 1 -C 6  alkyl, halogen, C 1 -C 6  haloalkyl, —OH, —O(alkyl), —O(haloalkyl), CN, and NO 2 ; 
         R 2g , at each occurrence, is independently C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , —OR y1 , —OC(O)R y2 , —OC(O)NR y3 R y4 , —SR y1 , —S(O) 2 R y1 , —S(O) 2 NR y3 R y4 , —C(O)R y1 , —C(O)OR y1 , —C(O)NR y3 R y4 , —NR y3 R y4 , —N(R y3 )C(O)R y2 , —N(R y3 )S(O) 2 R y2 , —N(R y3 )C(O)O(R y2 ), —N(R y3 )C(O)NR y3 R y4 , —N(R y3 )S(O) 2 NR y3 R y4 , G 2b , —(C 1 -C 6  alkylenyl)-OR, —(C 1 -C 6  alkylenyl)-OC(O)R y2 , —(C 1 -C 6  alkylenyl)-OC(O)NR y3 R y4 , —(C 1 -C 6  alkylenyl)-S(O) 2 R y1 , —(C 1 -C 6  alkylenyl)-S(O) 2 NR y3 R y4 , —(C 1 -C 6  alkylenyl)-C(O)R y1 , —(C 1 -C 6  alkylenyl)-C(O)OR y1 , —(C 1 -C 6  alkylenyl)-C(O)NR y3 R y4 , —(C 1 -C 6  alkylenyl)-NR y3 R y4 , —(C 1 -C 6  alkylenyl)-N(R y3 )C(O)R y2 , —(C 1 -C 6  alkylenyl)-N(R y3 )S(O) 2 R y2 , —(C 1 -C 6  alkylenyl)-N(R y3 )C(O)O(R y2 ), —(C 1 -C 6  alkylenyl)-N(R y3 )C(O)NR y3 R y4 , —(C 1 -C 6  alkylenyl)-N(R y3 )S(O) 2 NR y3 R y4 , —(C 1 -C 6  alkylenyl)-CN, or —(C 1 -C 6  alkylenyl)-G 2b ; 
         R y1 , R y3 , and R y4 , at each occurrence, are each independently H, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, G 2b , or —(C 1 -C 6  alkylenyl)-G 2b ; 
         R y2 , at each occurrence, is independently C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, G 2b , or —(C 1 -C 6  alkylenyl)-G 2b ; 
         G 2b , at each occurrence, is independently aryl, heteroaryl, cycloalkyl, cycloalkenyl, or heterocycle; and each G 2b  group is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, halogen, C 1 -C 6  haloalkyl, —CN, NO 2 , —OR z1 , —OC(O)R z2 , —OC(O)NR z3 R z4 , —SR z1 , —S(O) 2 R z1 , —S(O) 2 NR z3 R z4 , —C(O)R z1 , —C(O)OR z1 , —C(O)NR z3 R z4 , —NR z3 R z4 , —N(R z3 )C(O)R z2 , —N(R z3 )S(O) 2 R z2 , —N(R z3 )C(O)O(R z2 ), —N(R z3 )C(O)NR z3 R z4 , —N(R z3 )S(O) 2 NR z3 R z4 , —(C 1 -C 6  alkylenyl)-OR z1 , —(C 1 -C 6  alkylenyl)-OC(O)R z2 , —(C 1 -C 6  alkylenyl)-OC(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-S(O) 2 R z1 , —(C 1 -C 6  alkylenyl)-S(O) 2 NR z3 R z4 , —(C 1 -C 6  alkylenyl)-C(O)R z1 , —(C 1 -C 6  alkylenyl)-C(O)OR z1 , —(C 1 -C 6  alkylenyl)-C(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-NR z3 R z4 , —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)R z2 , —(C 1 -C 6  alkylenyl)-N(R z3 )S(O) 2 R z2 , —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)O(R z2 ), —(C 1 -C 6  alkylenyl)-N(R z3 )C(O)NR z3 R z4 , —(C 1 -C 6  alkylenyl)-N(R z3 )S(O) 2 NR z3 R z4 , and —(C 1 -C 6  alkylenyl)-CN; 
         R z1 , R z3 , and R z4 , at each occurrence, are each independently H, C 1 -C 6  alkyl, or C 1 -C 6  haloalkyl; and 
         R z2 , at each occurrence, is independently C 1 -C 6  alkyl or C 1 -C 6  haloalkyl. 
       
     
     
         26 . A compound of  claim 1  or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
 3-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]pyridin-3-yl)}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 N-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]ethanesulfonamide; 
 1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; 
 N-[4-(2,4-difluorophenoxy)-3-{5-[1-(ethylsulfonyl)piperidin-4-yl]-1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl}phenyl]ethanesulfonamide; 
 1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-N,N-dimethylmethanesulfonamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-7-oxo-N-(pyridin-3-ylmethyl)-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; 
 3-{2-(2,4-difluorophenoxy)-5-[(morpholin-4-ylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-ethyl-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 5-chloro-3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-N-methylmethanesulfonamide; 
 N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide; 
 N-[4-(2,4-difluorophenoxy)-2-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide; 
 3-{2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; 
 3-{2-[(4,4-difluorocyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; and 
 3-{2-[(cyclopropylmethyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one. 
 
     
     
         27 . A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to  claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
     
     
         28 . A method for treating cancer in a subject comprising administering a therapeutically effective amount of a compound of formula (I) according to  claim 1  or a pharmaceutically acceptable salt thereof, to a subject in need thereof. 
     
     
         29 . The method of  claim 28  wherein the cancer is selected from the group consisting of: acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenström's macroglobulinemia, testicular tumors, uterine cancer and Wilms' tumor. 
     
     
         30 . A method for treating a disease or condition in a subject comprising administering a therapeutically effective amount of a compound of formula (I) according to  claim 1  or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein said disease or condition is selected from the group consisting of Addison's disease, acute gout, ankylosing spondylitis, asthma, atherosclerosis, Behcet's disease, bullous skin diseases, cardiac myopathy, cardiac hypertrophy, chronic obstructive pulmonary disease (COPD), Crohn's disease, dermatitis, eczema, giant cell arteritis, glomerulonephritis, heart failure, hepatitis, hypophysitis, inflammatory bowel disease,), Kawasaki disease, lupus nephritis, multiple sclerosis, myocarditis, myositis, nephritis, organ transplant rejection, osteoarthritis, pancreatitis, pericarditis, Polyarteritis nodosa, pneumonitis, primary biliary cirrhosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, scleritis, sclerosing cholangitis, sepsis systemic lupus erythematosus, Takayasu's Arteritis, toxic shock, thyroiditis, type I diabetes, ulcerative colitis, uveitis, vitiligo, vasculitis, and Wegener's granulomatosis. 
     
     
         31 . A method for treating a chronic kidney disease or condition in a subject comprising administering a therapeutically effective amount of a compound of formula (I) according to  claim 1  or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein said disease or condition is selected from the group consisting of: diabetic nephropathy, hypertensive nephropathy, HIV-associated nephropathy, glomerulonephritis, lupus nephritis, IgA nephropathy, focal segmental glomerulosclerosis, membranous glomerulonephritis, minimal change disease, polycystic kidney disease and tubular interstitial nephritis. 
     
     
         32 . A method for treating an acute kidney disease or condition in a subject comprising administering a therapeutically effective amount of a compound of formula (I) according to  claim 1  or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein said acute kidney disease or condition is selected from the group consisting of: ischemia-reperfusion induced kidney disease, cardiac and major surgery induced kidney disease, percutaneous coronary intervention induced kidney disease, radio-contrast agent induced kidney disease, sepsis induced kidney disease, pneumonia induced kidney disease, and drug toxicity induced kidney disease. 
     
     
         33 . A method for treating an acquired immunodeficiency syndrome (AIDS) in a subject comprising administering a therapeutically effective amount of a compound of formula (I) according to  claim 1  or a pharmaceutically acceptable salt thereof, to a subject in need thereof. 
     
     
         34 . A method for treating a disease or condition in a subject comprising administering a therapeutically effective amount of a compound of formula (I) according to  claim 1  or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein said disease or condition is selected from the group consisting of: obesity, dyslipidemia, hypercholesterolemia, Alzheimer's disease, metabolic syndrome, hepatic steatosis, type II diabetes, insulin resistance, diabetic retinopathy and diabetic neuropathy. 
     
     
         35 . A method of contraception in a male subject comprising administering a therapeutically effective amount of a compound of formula (I) according to  claim 1  or a pharmaceutically acceptable salt thereof, to a subject in need thereof.